Anti-CD38 monoclonal antibodies in kidney disease: mechanistic rationale and emerging clinical evidence

Clicks: 23
ID: 332423
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #50 of 152 articles by views in nephrology dialysis transplantation

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 152 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Over the past decades, the therapeutic landscape of nephrology has been transformed by the expanding use of immunosuppressive therapies, reflecting major advances in our understanding of the roles of the innate and adaptive immune systems in the pathogenesis of kidney diseases. While B-cell depletion via rituximab or obinutuzumab has improved immune-mediated kidney disease management, these agents remain insufficient. They spare long-lived plasma cells, memory B cells, and innate effectors, permitting persistent antibody production and ongoing tissue injury. Consequently, increasing attention has focused on anti-CD38 monoclonal antibodies, including daratumumab, isatuximab, and felzartamab, which target several of these pathogenic immune cell populations. Early clinical experience and emerging trial data in diseases such as IgA nephropathy, primary membranous nephropathy, and, most notably, kidney transplantation have suggested potential benefits in selected settings, further supporting their potential role in nephrology. In this narrative review, we summarize the current understanding of the pathophysiological role of CD38-expressing immune cells in kidney diseases and critically evaluate the available clinical evidence on the use of anti-CD38 monoclonal antibody therapies across a spectrum of renal disorders. The review also compares the roles of anti-CD38 monoclonal therapies in native kidney disease and antibody-mediated rejection, since they differ in mechanism, clinical evidence, and treatment options.
Reference Key
openalex_W7222026186 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Mehmet Kanbay, Sidar Çöpür, Ibrahim Gulmaliyev, Caner Süsal, Adrian Covic, Mahmut Altındal
Are you one of these authors? Claim your profile
Journal nephrology dialysis transplantation
Year 2026
DOI
10.1093/ndt/gfag238
URL
https://doi.org/10.1093/ndt/gfag238
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.